Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | PARG | Q86W56 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510585 | 0.83 | ATR (0.37) | KRASHTR2CSLC6A4MAPK8CNR2 | |
| SCHEMBL6511027 | 0.83 | ATR (0.42) | PLK1CNR2CHEK1 | |
| SCHEMBL6521469 | 0.83 | ALDH1A1 (0.41) | KRASCNR1HTR2CSLC6A4CNR2 | |
| SCHEMBL6510992 | 0.83 | ALOX5AP (0.36) | KRASCNR1CNR2CHEK1 | |
| SCHEMBL6514165 | 0.81 | CHEK1 (0.39) | PARGCNR2CHEK1 | |
| SCHEMBL6514906 | 0.81 | CHEK1 (0.35) | P2RX3KRASHTR2CSLC6A4CNR2 | |
| SCHEMBL6507186 | 0.81 | HTR2C (0.41) | KRASHTR2CSLC6A4CNR2CHEK1 | |
| SCHEMBL6514701 | 0.80 | CHEK1 (0.36) | KRASHTR2CSLC6A4CNR2CHEK1 | |
| SCHEMBL6514903 | 0.79 | HTR2C (0.37) | KRASHTR2CSLC6A4CNR2CHEK1 | |
| SCHEMBL6516690 | 0.79 | CHEK1 (0.42) | MAPK8CNR2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | P2RX3 4637/4885PARG 4281/4885FEN1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.